Literature DB >> 27009455

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis.

Rahul Rajeev, Kiran K Turaga1.   

Abstract

BACKGROUND: Malignant peritoneal disease can lead to significant debility due to bowel obstructions, ascites, and cancer cachexia. Moreover, inadequate imaging techniques can lead to the suboptimal detection of disease, and the poor vascularity of tumors can lead to a poor response to systemic chemotherapy. However, combination cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising novel treatment for patients with this disease.
METHODS: The medical literature focusing on diagnostic updates and the management of peritoneal disease was reviewed. The application principles of HIPEC for use in peritoneal disease were also summarized.
RESULTS: Improvements in imaging and the application of laparoscopic techniques have significantly increased the rate of diagnosis of early peritoneal disease with consequently less morbid cytoreductive procedures. Appropriate patient selection based on prognostic scores along with complete cytoreduction can identify a cohort of patients likely to derive durable benefit from this combination treatment.
CONCLUSIONS: Advances in diagnostic and therapeutic techniques, including surgical cytoreductive techniques, have demonstrated significant survival gains in patients with peritoneal disease. Although HIPEC can be used for the management of various types of histologies, further development of high-level evidence is necessary to advance the field.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009455     DOI: 10.1177/107327481602300107

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  6 in total

Review 1.  Intraperitoneal immunotherapy: historical perspectives and modern therapy.

Authors:  W F Morano; A Aggarwal; P Love; S D Richard; J Esquivel; W B Bowne
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

2.  Racial Disparities in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Aggressive Surgical Treatment Overcome Cancer Health Inequities?

Authors:  Devon C Freudenberger; Xiaoyan Deng; Vignesh Vudatha; Andrea N Riner; Kelly M Herremans; Dipankar Bandyopadhyay; Leopoldo J Fernandez; Jose G Trevino
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) after High-Intensity Ultrasound (HIUS).

Authors:  Veria Khosrawipour; Sören Reinhard; Alice Martino; Tanja Khosrawipour; Mohamed Arafkas; Agata Mikolajczyk
Journal:  Int J Surg Oncol       Date:  2019-12-12

Review 4.  A Review of the Clinical Implications of Cachexia, Sarcopenia, and BMI in Patients with Peritoneal Carcinomatosis Receiving Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Devon C Freudenberger; Vignesh Vudatha; Andrea N Riner; Kelly M Herremans; Leopoldo J Fernandez; Jose G Trevino
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

5.  Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites.

Authors:  Jie Jiao; Chengzhen Li; Guanying Yu; Lei Zhang; Xiaoyan Shi; Jingdu Yan; Houjun Zhang; Peiming Guo
Journal:  World J Surg Oncol       Date:  2020-07-22       Impact factor: 2.754

6.  Intraperitoneal chemotherapy of the peritoneal surface using high-intensity ultrasound (HIUS): investigation of technical feasibility, safety and possible limitations.

Authors:  Hien Lau; Tanja Khosrawipour; Agata Mikolajczyk; Piotr Frelkiewicz; Jakub Nicpon; Mohamed Arafkas; Alessio Pigazzi; Wolfram Trudo Knoefel; Veria Khosrawipour
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.